Form 4: Seres Therapeutics Executive Matthew Henn Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, reports the vesting and selling of restricted stock units to cover taxes.

Summary

  • Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
  • The transactions involve the vesting and selling of restricted stock units (RSUs).
  • On May 15, 2025, 140 RSUs vested and settled, and another 98 RSUs vested and settled.
  • On May 16, 2025, 77 shares were sold at a price of $7.28 per share.
  • These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 13, 2023, to cover taxes associated with the vesting of the RSUs.
  • The reported transactions resulted in Henn owning 4,383 shares of common stock and 1,073 RSUs following the reported transactions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions by an executive under a pre-arranged plan.

Future Outlook

The remaining restricted stock units will continue to vest and settle in 12 equal quarterly installments.

Industry Context

Executive stock transactions are common and closely monitored, providing insights into management's perspective on the company's value and prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.

Key Dates

DateDescription
04/13/2023Rule 10b5-1 trading plan adopted by the reporting person.
02/15/202425% of the restricted stock units vested and settled.
02/15/202525% of the restricted stock units vested and settled.
04/21/20251-for-20 reverse stock split effected.
05/15/2025Vesting and settlement of 140 and 98 Restricted Stock Units.
05/16/2025Sale of 77 shares of common stock at $7.28 per share.
05/19/2025Date of Form 4 signature.

Keywords

Form 4, Seres Therapeutics, MCRB, Matthew Henn, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership, Stock Sale, Vesting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.